BACKGROUND: Studies aimed at defining the association between host immune responses and human immunodeficiency virus (HIV) persistence during therapy are necessary to develop new strategies for cure. METHODS: We performed a comprehensive assessment of ultrasensitive plasma HIV RNA levels, cell-associated HIV RNA levels, proviral HIV DNA levels, and T cell immunophenotyping in a cohort of 190 subjects in whom HIV levels were suppressed by highly active antiretroviral therapy. RESULTS: The median CD4(+) T cell count was 523 cells/mm(3), and the median duration of viral suppression was 31 months. Cell-associated RNA and proviral DNA levels (but not ultrasensitive plasma HIV RNA levels) were positively correlated with frequencies of CD4(+) and CD8(+) T cells expressing markers of T-cell activation/dysfunction (CD38, HLA-DR, CCR5, and/or programmed cell death protein 1 [PD-1]) (P < .05). Having a low CD4(+) T-cell count despite receipt of virologically suppressive therapy was associated with high cell-associated RNA and proviral DNA levels (P < .01) and higher frequencies of CD4(+) T cells expressing CD38, HLA-DR, CCR5, and/or PD-1 (P < .0001). CONCLUSIONS: Cell-based measurements of viral persistence were consistently associated with markers of immune activation and the frequency of PD-1-expressing CD4(+) T cells. Treated patients with a low CD4(+) T-cell count had higher frequencies of PD-1-expressing CD4(+) T cells and cell-based measures of viral persistence, suggesting that HIV infection in these individuals may be more difficult to cure and may require unique interventions.
BACKGROUND: Studies aimed at defining the association between host immune responses and human immunodeficiency virus (HIV) persistence during therapy are necessary to develop new strategies for cure. METHODS: We performed a comprehensive assessment of ultrasensitive plasma HIV RNA levels, cell-associated HIV RNA levels, proviral HIV DNA levels, and T cell immunophenotyping in a cohort of 190 subjects in whom HIV levels were suppressed by highly active antiretroviral therapy. RESULTS: The median CD4(+) T cell count was 523 cells/mm(3), and the median duration of viral suppression was 31 months. Cell-associated RNA and proviral DNA levels (but not ultrasensitive plasma HIV RNA levels) were positively correlated with frequencies of CD4(+) and CD8(+) T cells expressing markers of T-cell activation/dysfunction (CD38, HLA-DR, CCR5, and/or programmed cell death protein 1 [PD-1]) (P < .05). Having a low CD4(+) T-cell count despite receipt of virologically suppressive therapy was associated with high cell-associated RNA and proviral DNA levels (P < .01) and higher frequencies of CD4(+) T cells expressing CD38, HLA-DR, CCR5, and/or PD-1 (P < .0001). CONCLUSIONS: Cell-based measurements of viral persistence were consistently associated with markers of immune activation and the frequency of PD-1-expressing CD4(+) T cells. Treated patients with a low CD4(+) T-cell count had higher frequencies of PD-1-expressing CD4(+) T cells and cell-based measures of viral persistence, suggesting that HIV infection in these individuals may be more difficult to cure and may require unique interventions.
Authors: Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano Journal: Nat Med Date: 2003-05-18 Impact factor: 53.440
Authors: Timothy W Schacker; Cavan Reilly; Gregory J Beilman; Jodie Taylor; David Skarda; David Krason; Matthew Larson; Ashley T Haase Journal: AIDS Date: 2005-12-02 Impact factor: 4.177
Authors: T W Chun; L Carruth; D Finzi; X Shen; J A DiGiuseppe; H Taylor; M Hermankova; K Chadwick; J Margolick; T C Quinn; Y H Kuo; R Brookmeyer; M A Zeiger; P Barditch-Crovo; R F Siliciano Journal: Nature Date: 1997-05-08 Impact factor: 49.962
Authors: Lydie Trautmann; Loury Janbazian; Nicolas Chomont; Elias A Said; Sylvain Gimmig; Benoit Bessette; Mohamed-Rachid Boulassel; Eric Delwart; Homero Sepulveda; Robert S Balderas; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sekaly Journal: Nat Med Date: 2006-08-20 Impact factor: 53.440
Authors: Tzong-Hae Lee; Daniel M Chafets; William Reed; Li Wen; Yunting Yang; Jennifer Chen; Garth H Utter; John T Owings; Michael P Busch Journal: Transfusion Date: 2006-11 Impact factor: 3.157
Authors: Tzong-Hae Lee; Teresa Paglieroni; Garth H Utter; Daniel Chafets; Robert C Gosselin; William Reed; John T Owings; Paul V Holland; Michael P Busch Journal: Transfusion Date: 2005-08 Impact factor: 3.157
Authors: Peter W Hunt; Jeffrey N Martin; Elizabeth Sinclair; Barry Bredt; Elilta Hagos; Harry Lampiris; Steven G Deeks Journal: J Infect Dis Date: 2003-04-23 Impact factor: 5.226
Authors: Jesper F Højen; Thomas A Rasmussen; Karen Lise D Andersen; Anni A Winckelmann; Rune R Laursen; Jesper D Gunst; Holger J Møller; Mayumi Fujita; Lars Østergaard; Ole S Søgaard; Charles A Dinarello; Martin Tolstrup Journal: Mol Med Date: 2015-04-14 Impact factor: 6.354
Authors: Ross A Pollack; R Brad Jones; Mihaela Pertea; Katherine M Bruner; Alyssa R Martin; Allison S Thomas; Adam A Capoferri; Subul A Beg; Szu-Han Huang; Sara Karandish; Haiping Hao; Eitan Halper-Stromberg; Patrick C Yong; Colin Kovacs; Erika Benko; Robert F Siliciano; Ya-Chi Ho Journal: Cell Host Microbe Date: 2017-04-12 Impact factor: 21.023
Authors: Peter W Hunt; Elizabeth Sinclair; Benigno Rodriguez; Carey Shive; Brian Clagett; Nicholas Funderburg; Janet Robinson; Yong Huang; Lorrie Epling; Jeffrey N Martin; Steven G Deeks; Curtis L Meinert; Mark L Van Natta; Douglas A Jabs; Michael M Lederman Journal: J Infect Dis Date: 2014-04-21 Impact factor: 5.226
Authors: Sulggi A Lee; Elizabeth Sinclair; Vivek Jain; Yong Huang; Lorrie Epling; Mark Van Natta; Curtis L Meinert; Jeffrey N Martin; Joseph M McCune; Steven G Deeks; Michael M Lederman; Frederick M Hecht; Peter W Hunt Journal: J Infect Dis Date: 2014-02-28 Impact factor: 5.226
Authors: Damalie Nakanjako; Agnes N Kiragga; Beverly S Musick; Constantin T Yiannoutsos; Kara Wools-Kaloustian; Lameck Diero; Patrick Oyaro; Emanuel Lugina; John C Ssali; Andrew Kambugu; Philippa Easterbrook Journal: AIDS Date: 2016-07-31 Impact factor: 4.177